This site is intended for healthcare professionals
Latest drug news
  • Home
  • /
  • News
  • /
  • 2015
  • /
  • 09
  • /
  • AMG 416 (etelcalcetide) filed with EU for secondar...
Drug news

AMG 416 (etelcalcetide) filed with EU for secondary hyperparathyroidism- Amgen

Read time: 1 mins
Last updated:4th Sep 2015
Published:4th Sep 2015
Source: Pharmawand

Amgen announced the submission of a Marketing Authorisation Application to the European Medicines Agency via the centralised procedure for etelcalcetide (formerly AMG 416) for the treatment of secondary hyperparathyroidism (SHPT) in adult patients with chronic kidney disease (CKD) on haemodialysis therapy. If approved, etelcalcetide will be the first calcimimetic agent that can be administered intravenously.

The MAA submission for etelcalcetide includes data from three Phase III studies, all of which met their primary endpoints, including two pooled placebo-controlled trials in more than 1,000 patients and a head-to-head study evaluating etelcalcetide compared with cinacalcet.

Comment: AMG 416 is administered intravenously three times per week during CKD patients' haemodialysis treatments versus the blockbuster Sensipar/Mimpara (also an Amgen drug), which is an oral calcimimetic taken daily during dialysis.

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.